Filing Flows › Revolution Medicines (RVMD) › Guidance history
Revolution Medicines (RVMD) guidance history: what it guided and what it reported
Revolution Medicines gave guidance in 13 earnings releases on file since Nov 6, 2023.
GAAP operating expenses
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $1.6B–$1.7B (Feb 25, 2026) → raised $1.7B–$1.8B (May 6, 2026) | — | to be reported | — |
GAAP net income
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2025 | $840M–$900M (Feb 26, 2025) → reaffirmed $840M–$900M (May 7, 2025) → raised $1.0B–$1.1B (Aug 6, 2025) → reaffirmed $1.0B–$1.1B (Nov 5, 2025) | — | — | — |
| FY2024 | $480M–$520M (Feb 26, 2024) → reaffirmed $480M–$520M (May 8, 2024) → raised $560M–$600M (Aug 7, 2024) → reaffirmed $560M–$600M (Nov 6, 2024) | — | — | — |
| FY2023 | $385M–$415M (Nov 6, 2023) | — | — | — |
Stock-based compensation
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $180M–$200M (Feb 25, 2026) → raised $260M–$280M (May 6, 2026) → raised $270M–$290M (Aug 5, 2026) | — | to be reported | — |
| FY2025 | $115M–$130M (Feb 26, 2025) → reaffirmed $115M–$130M (May 7, 2025) → reaffirmed $115M–$130M (Aug 6, 2025) → reaffirmed $115M–$130M (Nov 5, 2025) | — | — | — |
| FY2024 | $70.0M–$80.0M (Feb 26, 2024) → reaffirmed $70.0M–$80.0M (May 8, 2024) → reaffirmed $70.0M–$80.0M (Aug 7, 2024) → reaffirmed $70.0M–$80.0M (Nov 6, 2024) | — | — | — |
| FY2023 | $45.0M (Nov 6, 2023) | — | — | — |
The latest quarter
Revolution Medicines, Q3 2026: revenue $198M, operating margin -188.9%, net loss $407M, operating cash flow −$416M. The chart follows the revenue to costs, profit and cash.
Questions
Does Revolution Medicines beat its guidance?
Revolution Medicines gave guidance in 13 earnings releases on file since Nov 6, 2023.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.